Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutual Recognition's Next Evolution May Be Sharing Info On India And China Inspections

Executive Summary

Now that US FDA has approved the final EU authority, mutual recognition efforts could expand and deepen. Former FDA chief counsel Rebecca Wood discusses the future of approval standards harmonization in Pink Sheet interview.

Advertisement

Related Content

House Committee Wants Answers On Foreign Inspections And Valsartan Crisis
Germany Joins EU-US Inspections MRA
Orphan Products: US FDA Working On ‘Sameness’ Policy For Cell And Gene Therapies
ICH Generic Drug Harmonization May Be Another Cost-Lowering Opportunity
US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large
Data Integrity And The Iceberg Concern
US FDA’s Lowell Schiller Steps In As Acting Chief Counsel When Rebecca Wood Departs In July
US Reliance On EU Drug Facility Inspections Begins In November
FDA Encourages Pediatric Master Protocols With Bayesian Approach

Topics

Advertisement
UsernamePublicRestriction

Register

PS125599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel